| [1] |
王海燕．肾脏病临床概览[M]. 北京：北京大学医学出版社，2009：121-127.
|
| [2] |
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis [J]. Kidney Inter Suppl, 2012, 2(1): 139-274.
|
| [3] |
傅君舟．成人难治性肾病综合征治疗的免疫抑制剂选择[J/CD]. 中华肾病研究电子杂志，2015，4(6)：281-285.
|
| [4] |
Manrique J, Cravedi P. Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases [J]. Nefrologia, 2014, 34(3): 388-397.
|
| [5] |
Mallat SG, Itani HS, Abou-Mrad RM, et al. Rituximab use in adult primary glomerulopathy: where is the evidence? [J]. Ther Clin Risk Manag, 2016, 12: 1317-1327.
|
| [6] |
何维，医学免疫学第二版[M]. 北京：人民卫生出版社，2010：177-178.
|
| [7] |
张英楠，涂阳科．利妥昔单抗应用于原发性膜性肾病的研究进展[J]. 中国新药与临床杂志，2016，35(5)：305-310.
|
| [8] |
Perez-Callejo D, Gonzalez-Rincon J, Sanchez A, et al. Action and resistance of monoclonal CD20 antibodies therapy in B-cell non-Hodgkin lymphomas [J]. Cancer Treat Rev, 2015, 41: 680-689.
|
| [9] |
付平，苟慎菊．利妥昔单抗在肾脏疾病中的应用[J]. 肾脏病与透析肾移植杂志，2017，26(1)：50-51.
|
| [10] |
Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome [J]. J Am Soc Nephrol, 2014, 25(4): 850-863.
|
| [11] |
Munyentwali H, Bouachi K, Audard V, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease [J]. Kidney Int, 2013, 83(3): 511-516.
|
| [12] |
Niu XL, Hao S, Wang P, et al. Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome [J]. Biomed Rep, 2016, 5(2): 237-242.
|
| [13] |
Sinha A, Bhatia D, Gulati A, et al. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome [J]. Nephrol Dial Transplant, 2015, 30(1): 96-106.
|
| [14] |
Roccatello D, Sciascia S, Di Simone D, et al. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature [J]. Autoimmun Rev, 2016, 15(6): 529-538.
|
| [15] |
李英，利妥昔单抗在特发性膜性肾病中的应用[J]. 肾脏病与透析肾移植杂志，2017，26(1)：54-55.
|
| [16] |
Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up [J]. J Am Soc Nephrol, 2017, 28(1): 348-358.
|
| [17] |
Suyama K, Kawasaki Y, Miyazaki K, et al. Rituximab and low-dose cyclosporine combination therapy for steroid resistant focal segmental glomerulosclerosis [J]. Pediatr Int, 2016, 58(3): 219-223.
|
| [18] |
Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient′s care [J]. Lancet, 2015, 385(9981): 1983-1992.
|
| [19] |
Ma H, Sandor DG, Beck LH Jr. The role of complement in membranous nephropathy [J]. Semin Nephrol, 2013, 33(6): 531-542.
|
| [20] |
Wang X, Cui Z, Zhang YM, et al. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort [J]. Nephrol Dial Transplant, 2018, 33(9): 1558-1563.
|
| [21] |
Vivarelli M, Massella L, Ruggiero B, et al. Minimal change disease [J]. Clin J Am Soc Nephrol, 2017, 12(2): 332-345.
|
| [22] |
Madanchi N, Bitzan M, Takano T. Rituximab in minimal change disease: mechanisms of action and hypotheses for future studies [J]. Can J Kidney Health Dis, 2017, 4: 1-15.
|
| [23] |
Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis [J]. Sci Transl Med, 2011, 3: 85.
|
| [24] |
Königshausen E, Sellin L. Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates [J]. Biomed Res Int, 2016, 2016: 376560.
|
| [25] |
Maas RJ, Deegens JK, Smeets B, et al. Minimal change disease and idiopathic FSGS: manifestations of the same disease [J]. Nat Rev Nephrol, 2016, 12(12): 768-776.
|
| [26] |
Magnasco A, Ravani P, Edefonti A, et al. Rituximab in children with resistant idiopathic nephrotic syndrome [J]. J Am Soc Nephrol, 2012, 23(6): 1117-1124.
|
| [27] |
Sadowski CE, Lovric S, Ashraf S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome [J]. J Am Soc Nephrol, 2015, 26(6): 1279-1289.
|
| [28] |
Basu B, Mahapatra TK, Mondal N. Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome [J]. Pediatrics, 2015, 136(1): e132-e139.
|
| [29] |
Fujinaga S, Someya T, Watanabe T, et al. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab [J]. Eur J Pediatr, 2013, 172(4): 513-518.
|
| [30] |
Cravedi P, Remuzzi G, Ruggenenti P. Rituximab in primary membranous nephropathy: first-line therapy, why not? [J]. Nephron Clin Pract, 2014, 128(3-4): 261-269.
|
| [31] |
Königshausen E, Sellin L. Recent treatment advances and new trials in adult nephrotic syndrome [J]. Biomed Res Int, 2017, 2017: 7689254.
|
| [32] |
Fujinaga S, Sakuraya K. Single infusion of low-dose ofatumumab in a child with complicated nephrotic syndrome with anti-rituximab antibodies [J]. Pediatr Nephrol, 2018, 33(3): 527-528.
|